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AD, atopic dermatitis; CE, corniﬁed
envelope; FLG, ﬁlaggrin gene;
KLK, kallikrein; NMF, natural moisturizing
factor; PCA, pyrrolidine carboxylic acid;
SC, stratum corneum; SG, stratum
granulosum; SPR, small proline-rich
protein; TG, transgultaminase; TJ, tight
junction; UCA, urocanic acid
a b s t r a c t
The skin is continuously exposed to external pathogens, and its barrier function is critical for skin ho-
meostasis. Previous studies have shown that the barrier dysfunction is one of the most predisposing
factors for the development of skin allergic diseases such as atopic dermatitis. In this article, we sum-
marize how the physical barrier of the skin is organized and review its link to the pathomechanism of
skin allergic diseases. We describe the formation of the SC barrier in terms of the following ﬁve cate-
gories: 1) ﬁlaggrin metabolism; 2) corniﬁed envelope; 3) intercellular lipids; 4) corneodesmosome; and
5) corneocyte desquamation. New approaches to restoring the skin barrier function are also discussed.
Copyright © 2017, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The skin covers the entire body and protects us from various
kinds of external stimuli. An impaired epidermal barrier allows the
enhanced penetration of external antigens and readily induces skin
inﬂammation. This facilitates the interaction of external antigens
with local immune cells and may lead to systemic immune re-
sponses.1 This is called the “outside-to-inside” hypothesis, and it
explains the association between skin barrier dysfunction and an
increased risk of developing allergic diseases, including atopic
dermatitis (AD), asthma, food allergies, and allergic rhinitis.2,3 In
addition, it is evident that persistent skin inﬂammation, in turn,
causes further attenuation of the skin barrier, suggesting the exis-
tence of an exacerbation loop between the skin barrier and skin
immunity (the “outside-to-inside-and-back-to-outside” hypothe-
sis).4,5 These observations suggest that maintaining the skin barrier
function is important not only for effective management of allergic
diseases but also for preventing their development.
The barrier function of the skin is largely dependent on the
stratum corneum (SC), the outermost layer of the epidermis
(Fig. 1A). The SC is formed through a course of tightly regulated
processes of keratinocyte differentiation called keratinization.6
Keratinization is achieved by keratinocytes passing through four
cell layers of the epidermis: the stratum basale, the stratum spi-
nosum, the stratum granulosum (SG), and the SC. In the SG, kera-
tinocytes start to produce two membrane-circumscribed granules:
keratohyalin granules and lamellar bodies (Fig. 1B). Keratohyalin
granules contain intracellular components of the SC (such as
ﬁlaggrin [FLG], loricrin, and keratin ﬁlaments), whereas lamellar
bodies contain extracellular components (such as lipids, corneo-
desmosin, and kallikreins). In the SC, keratinocytes are ﬂattened
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and denucleated (which are then called as corneocytes) and
simultaneously, corneocyte cell membranes are replaced by a
speciﬁc barrier structure called a corniﬁed envelope (CE). At the
transition from the SG to the SC, lamellar bodies are secreted into
the intercellular space of corneocytes and ﬁll it upwith lipids. These
structures are often described as bricks (corneocytes) and mortar
(intercellular lipids) (Fig. 1C).
Here, we describe the formation of the SC barrier in terms of the
following ﬁve categories to review their link to the pathogenesis of
skin allergic diseases: 1) FLG metabolism; 2) CE; 3) intercellular
lipids; 4) corneodesmosome; and 5) corneocyte desquamation. The
genes involved in each process are listed in Table 1. This review is an
updated version of a similar article that has published in the Journal
of Allergy and Clinical Immunology.3
Filaggrin metabolism
FLG and its metabolites are key components for maintaining
normal skin barrier function (Fig. 2).7,8 In the SG, FLG is produced as
FLG polymer (proﬁlaggrin), in which 10e12 repeats of FLG mono-
mer are linked, and stored in keratohyalin granules. At the transi-
tion from the SG to the SC, proﬁlaggrin is cleaved to generate FLG
monomers by proteases such as CAP1/Prss8 and SASPase/
ASPRV1.9,10 FLG monomers bind to keratin ﬁlaments and this
keratin-FLG bundle is a fundamental structure in corneocytes. At
the upper layer of the SC, FLG is re-dissociated from keratin
ﬁlaments to further metabolism. In this process, the citrullination
of FLG and keratin1 by peptidylarginine deiminase is considered
essential.11 The released FLG monomers are degraded to free amino
acids, including glutamine, arginine, and histidine, and then con-
verted into urocanic acid (UCA) and pyrrolidine carboxylic acid
(PCA). This process is mediated by other sets of proteases, including
caspase14, calpain1, and bleomycin hydrolase.12,13 UCA is an
important ultraviolet-absorbing chromophore in the SC and also
contributes to maintaining the acidic pH of the skin.14 Recent study
has shown that UCA signiﬁcantly reduced costimulatory molecule
expression on dendritic cells and increased their ability to induce a
regulatory Tcells.15 In contrast, PCA is amajor constituent of natural
moisturizing factors (NMFs), which are responsible for retaining
water in the SC. Therefore, FLG and its metabolites assume a
manifold role in the barrier function of the SC. Gene targeting
studies have revealed that FLG-deﬁcient mice demonstrate a
reduced SC barrier function with enhanced sensitization.16
Furthermore, on a proallergic BALB/c background, FLG-deﬁcient
mice develop spontaneous dermatitis.17
Filaggrin deﬁciency in the skin allergy
AD is the most common inﬂammatory skin disease, and has
multiple etiologies. Over the last decade, data from both experi-
mental models and patients have highlighted the primary patho-
genic role of skin barrier deﬁciency in AD.18e20 Particularly, loss-of-
Fig 1. A, The structure of the epidermis. The red line represents tight junctions in the stratum granulosum. B, Magniﬁed view of the cell in the stratum granulosum. C, The “bricks
and mortars” structure of the stratum corneum.
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function mutations in the FLG gene are strongly associated with the
development of AD as well as with ichthyosis vulgaris.18,21 The
prevalence of FLGmutations in AD patients ranges from25 to 50% in
the Northern European and Asian populations.22,23 In addition,
genome-wide association studies (GWAS) among individuals with
European, African, Japanese, and Latino ancestry have identiﬁed 31
risk loci of AD, to date, and among them, the mutation in FLG is
proved to be the strongest risk factor.24 These observations indicate
the major contribution of FLG-deﬁciency in AD pathogenesis.
Although mutations in FLG are common in Northern European
and Asian subjects, FLG mutations are less common in Southern
Europe,25 and are even absent in some African countries.26,27 A
recent study showed that the expression of another skin barrier
protein, FLG2, is reduced in the epidermis of AD patients.28 Further,
a nonsense mutation in the FLG2 gene was shown to be associated
with persistent AD patients of African ancestry.29 The biological
function of FLG2 remains to be elucidated, but its structure, pattern
of expression, and biological properties are very similar to FLG.
Therefore, FLG2 may also play important roles in skin barrier
integrity. We must also note the possibility that FLG deﬁciency
might be compensable under a tropical climate.30
Formation of the corniﬁed envelope
The corniﬁed envelope (CE) is a speciﬁc barrier structure formed
beneath the cell membrane of corneocytes (Fig. 3).31 The CE con-
sists of highly crosslinked insoluble proteins and the extracellular
lipids anchoring on it. This structure acts as a vital physical barrier
to the SC.
The assembly of the CE starts in the upper layer of the stratum
spinosum. In response to the elevation of intracellular Ca2þ levels,
keratinocytes produce envoplakin, periplakin, and involucrin.
Envoplakin and periplakin form heterodimers, and, together with
involucrin, they accumulate beneath the plasma membrane.32
These three proteins are crosslinked to each other by trans-
glutaminase (TG) 1 and TG5.33 Involucrin acts as a scaffold of the CE,
Table 1
A list of genes which regulate stratum corneum formation.
Gene Gene symbol Function Associated human disease Knockout mice phenotype Reference
FLG metabolism Filaggrin FLG Keratin ﬁlaments
aggregation
Ichthyosis vulgaris, AD Skin barrier deﬁciency
Spontaneous dermatitis
16e18,21
Filaggrin2 FLG2 Similar to FLG? AD? 29
Cap1/Prss8 PRSS8 Cleave proFLG to FLG Skin barrier deﬁciency 9
SASpase ASPRV1 Cleave proFLG to FLG AD? SC dehydration 10
Peptidylarginine
deiminase
PADI Citrullilation of FLG 11
Caspase14 CASP14 FLG metabolism Skin barrier deﬁciency 12
Calpain1 CAPN1 FLG metabolism 13
Bleomycin
hydrolase





Involucrin IVL Scaffold of CE No skin phenotype 36
Envoplakin EVPL Plakin family No skin phenotype 37
Periplakin PPL Plakin family No skin phenotype 38
Loricrin LOR Reinforce CE Shiny skin 40
Small proline-rich
protein
SPRR Reinforce CE 96
Transglutaminase 1 TGM1 Crosslink CE proteins ARCI1 Skin barrier deﬁciency 41,97
Transglutaminase 3 TGM3 Crosslink CE proteins Skin barrier deﬁciency 98



















Skin barrier deﬁciency 47,101
Tmem79/mattrin TMEM79 Secretion of lamellar
bodies
AD? Spontaneous dermatitis 48,49
Corneodesmosome Desmoglein1 DSG1 Cadherin family SAM syndrome 51
Desmocollin1 DCN1 Cadherin family Skin barrier deﬁciency 102
Plakoglobin JUP Armadillo family Naxos disease Embryonic lethal 103
Plakophilin PKP Armadillo family Skin fragility syndrome PKP3-deﬁcient mice
develop dermatitis
104
(Envoplakin) EVPL Plakin family No skin phenotype 37
(Periplakin) PPL Plakin family No skin phenotype 38
Corneodesmosin CDSN Support the
corneodesmosome
adhesion





Kallikrein5 KLK5 Serine protease Skin inﬂammation
(when overexpressed)
106
Kallikrein7 KLK7 Serine protease AD? Skin inﬂammation
(when overexpressed)
107
















The diseases that represent allergic manifestations are shown in bold.
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while plakin dimers act as a binding site of keratin ﬁlaments and
combine them with desmosomal proteins. Importantly, since pla-
kin proteins are tightly crosslinked to the involucrin scaffold, des-
mosomes and keratin ﬁlaments are rigidly linked on the CE, which
confers mechanical stability to corneocytes.
In the SG, loricrin and small proline-rich (SPR) protein families
are produced. These proteins are crosslinked by TG3 and trans-
locate to the cell periphery; next they crosslink onto the pre-
existing scaffold of involucrin by TG1 and TG5.34 To reinforce the
CE, this crosslinking is repeated and as the result, up to 80% of the
CE protein consists of loricrin. TG1 also combines extracellular
ceramide lipids onto the scaffold of involucrin, and eventually, the
ceramides replace the lipid bilayer of the plasma membrane.35 This
step is further described in section “Formation of intercellular lipid
lamellae”.
Corniﬁed envelope formation in the skin allergy
Despite the ubiquitous presence of involucrin, envoplakin, and
periplakin in the CE, single knockout mice of these genes do not
show any obvious skin abnormalities.36e38 The triple knockout of
these three genes results in abnormal CE formation with reduced
lipid content and decreased mechanical integrity, but the skin
barrier function is normal (possibly compensated by reduced
desquamation of corneocytes).39 Similarly, loricrin-deﬁcient mice
exhibit only a subtle phenotype, with shiny skin at birth and
reduced CE stability.40 These studies suggest that CE proteins are
redundant and indicate the existence of strong compensatory
mechanisms. In accordance with this notion, no mutations of the
genes of CE components have been linked to the pathogenesis of
skin allergic diseases thus far.
The CE is abnormal or even absent with TG1-deﬁciency, in
which severe ichthyosiform erythroderma (autosomal recessive
congenital ichthyosis [ARCI] 1) develops.41 In addition, TG5 deﬁ-
ciency causes peeling skin syndrome 2, which represents as su-
perﬁcial acral skin peeling occurring at the junction between the SG
and the SC.42 These facts suggest the non-redundant role of TGs in
the formation of CE; however, the association between genetic
mutation in TGs and skin allergic diseases has not been reported.
Formation of intercellular lipid lamellae
The intercellular lipids (the “mortar”) are also an integral
component of the SC barrier (Fig. 3). They consist of a heteroge-
neous mixture of ceramides, free fatty acids, and cholesterol in a
roughly 1:1:1M ratio. These lipids are produced in the SG and
stored in lamellar bodies, and are subsequently secreted into
extracellular space in the transition to the SC. In the ceramide
fraction alone, over 300 distinct species have been identiﬁed from
human SC.43 Among them, omega-hydroxyceramide is indispens-
able because it is conjugated to the involucrin scaffold by TG1 and
covers the surface of corneocytes. Using this ceramide as a tem-
plate, periodic sheets of lipid lamellae are formed in the intercel-
lular space of corneocytes.44
Intercellular lipid lamellae formation in the skin allergy
Several defects in ceramide-processing enzymes have been
linked to the etiology of barrier-deﬁcient skin diseases. 12R-lip-
oxygenase (encoded in the ALOX12B gene) and epidermal
lipoxygenase-3 (encoded in the ALOXE3 gene) are both essential for
the generation of omega-hydroxyceramide.45 Defect in these pro-
teins causes congenital ichthyosis (ARCI2, and ARCI3, respec-
tively).46 The skin manifestations of ARCI2 and ARCI3 are less
severe than those of ARCI1, probably because the protein layer of
the CE is formed in these diseases.
The transmembranal transport of lamellar bodies is conducted
by a lipid transporter called ATP-binding cassette subfamily A
member 12 (ABCA12).47 Mutations of this gene result in moderate
(ARCI4A) to severe (ARCI4B, also known as harlequin ichthyosis)
congenital ichthyosis, suggesting an essential role of lamellar body
contents in normal corniﬁcation. Recently, transmembrane protein
79/mattrin (Tmem79/Matt) was identiﬁed to be involved in the
secretion of lamellar body contents.48,49 Tmem79 is a ﬁve-
transmembrane protein that is localized to lamellar bodies, and
Tmem79-deﬁcient mice exhibit spontaneous dermatitis with
elevated serum IgE, which resembles human AD manifestations. In
addition, a meta-analysis of AD patients revealed that a missense
mutation of the TMEM79 gene has a small but signiﬁcant association
with AD.49 These ﬁndings suggest that the abnormality of the
lamellar body function and subsequent intercellular lipid layer
dysformationmight result in barrier deﬁciency in someADpatients.
Structure of corneodesmosome
The cell adhesion of corneocytes is dependent on the desmo-
some apparatus, called the corneodesmosome (Fig. 3). The
Fig 2. Schema of the FLG metabolic process. In the stratum granulosum, proﬁlaggrins
are stored in keratohyalin granules and then cleaved into FLG monomers. FLG
monomers bind to keratin ﬁlaments in corneocytes. At the upper layer of the SC, FLG
monomers are released from keratins and cleaved into free amino acids, followed by
conversion into PCA and UCA.
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desmosome is composed of three protein families: desmosomal
cadherin, armadillo proteins, and plakins. In the corneodesmo-
some, desmoglein 1 and desmocollin 1 (cadherin family) interact
with plakoglobin and plakophilins (armadillo proteins), which
attach to envoplakin and periplakin. As described above, envopla-
kin and periplakin heterodimers are crosslinked to the involucrin
scaffold, and bind keratin ﬁlaments on its C-terminus. The cor-
neodesmosin is another important modulator of corneodesmoso-
mal adhesion.50 It is stored in the lamellar bodies and secreted into
the intracellular space of the SC, and interacts with cadherin pro-
teins to support their adhesion.
Corneodesmosome formation in the skin allergy
Abnormality of the corneodesmosome is prone to cause hyper-
desquamation of corneocytes, whichmay lead to skin barrier defect
and subsequent skin inﬂammation. A recent study revealed that the
homozygous mutation of desmoglein 1 results in severe dermatitis
(erythroderma), accompanied by palmoplantar keratoderma,
hypotrichosis, and increased serum IgE (EPKHE, also known as
severe dermatitis, multiple allergies, and metabolic wasting [SAM]
syndrome).51 Importantly, EPKHE patients often have multiple food
allergies. In contrast, the homozygous mutation of the corneo-
desmosin causes peeling skin syndrome 1, characterized by
dermatitis, severe pruritus, food allergies, repeated episodes of
angioedema and urticaria, asthma, and increased serum IgE.52
Corneocyte desquamation
At the surface layer of the SC, corneocytes are constantly shed.
This phenomenon is called desquamation, and it is an important
process to maintain the SC homeostasis. Corneocyte desquamation
is mainly regulated by a proteolytic cascade of kallikrein (KLK)-
related peptidases, such as KLK5, KLK7, and KLK14.53 The activity of
these proteases is pH-dependent and is enhanced when the pH in
the SC is elevated. Their activity is also strictly regulated by a
cocktail of protease inhibitors, including lymphoepithelial Kazal-
type 5 serine protease inhibitor (LEKTI) encoded by the serine
protease inhibitor Kazal-type 5 (SPINK5).54 KLKs and LEKTI are
stored in lamellar bodies and secreted into the intercellular space at
the SG-SC interface.
Corneocyte desquamation in the skin allergy
In AD patients, the skin surface pH is increased, at least partially
due to the decreased production of UCA derived from FLG (Fig. 2).55
As such, KLK activity is often enhanced in the AD skin. This con-
dition is thought to induce an adverse effect on the SC barrier
through a multimodal mechanism (Fig. 4). First, KLKs cleave cor-
neodesmosomal cadherins and promote corneocyte desquamation.
Second, KLKs activate protease-activated receptor (PAR)-2, a G-
protein-coupled receptor on keratinocytes. Upon activation, PAR-2
signals lead to suppression of lamellar body secretion via the
downregulation of lipid processing enzymes.56 Finally, activated
KLKs increase the generation of interleukin (IL)-1a and IL-1b,
whose preforms are abundantly stored in the cytosol of corneo-
cytes. Indeed, IL-1 cytokines are increased in the SC of AD patients
and their enhanced production is associated with FLG deﬁciency.57
Two genetic polymorphisms that result in increased KLKs activity
have been linked to AD pathogenesis: gain-of-function mutations in
KLK7 and loss-of-function mutations in SPINK5. The 4bp insertion
polymorphism of KLK7 was ﬁrst reported in the UK,58 but their as-
sociation with AD was not found in a French AD cohort study.59
SPINK5 is known as the gene responsible for Netherton syndrome
in which patients display a broad range of allergic manifestations,
such as AD-like dermatitis, food allergies, asthma, hay fever, and
Fig 3. The structures of the corniﬁed envelope and corneodesmosome. Involucrin forms the scaffold and is reinforced by loricrin and SRRs. Envoplakin-periplakin heterodimers
conjugate keratin ﬁlaments.
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markedly elevated serum IgE levels.60 A signiﬁcant association of
polymorphism in SPINK5with AD was reported in the UK and Asian
populations,61e63 but not found in the French population.59
Tight junction in the skin allergy
In addition to the SC, tight junctions (TJs) are structures that are
essential to the integrity of the skin barrier. In the skin, TJs seal
adjacent keratinocytes in the SG (Fig. 1A) and act as a barrier for
water and solutes.64 TJs are composed of transmembrane proteins,
such as the claudin and occludin family, and several cytosolic
scaffold proteins, including zonulae occludens (ZOs). The indis-
pensable role of TJs in skin homeostasis was ﬁrst demonstrated by
claudin1-deﬁcient mice that died within 24 h of birth with severe
dehydration.65 Importantly, these mice had no abnormalities in the
production of SC components. A recent study with AD model mice
showed that the expression of TJ proteins was suppressed with skin
inﬂammation, but was not affected by FLG deﬁciency.66
In humans, the claudin1 expression is reduced in the non-
lesional skin of AD patients, and the association of claudin1 poly-
morphism with AD susceptibility has been reported.67 These ob-
servations suggest that an impairment in TJs contributes to the
barrier dysfunction observed in AD patients. Since most of the skin
is covered with the SC, TJs seem to act as the second line of defense
against external pathogens; however, TJs must be the primary
barrier structure in skin appendages, such as hair follicles and
sweat glands, because the SC is absent in these areas. Indeed, it is
well known that hair follicles are important shunt routes into the
skin for drugs and chemicals.68 In accordance with this notion,
widespread eruptive infections with herpes simplex virus or mol-
luscum contagiosum virus, which enter the body through hair fol-
licles, sometimes occur as a complication of AD.69,70 These facts
suggest that the skin appendages are the “security holes” of the
skin, particularly in AD patients with TJ deﬁciency.
Immunological modulation of skin barriers
Accumulating evidence suggests that immune cells inﬂuence
skin integrity through the production of cytokines.71,72 Although
complex interaction of immune cells creates AD skin lesions, the
immunopathogenesis of AD is characterized by Th2-skewed re-
sponses.73,74 Previous studies have shown that IL-4 and IL-13, the
two major Th2 cytokines, downregulate the production of 1) FLG
and keratins, 2) the CE components (loricrin and involucrin), 3) cell
adhesionmolecules (desmogleins, ZO-1), and 4) ceramide lipids. IL-
31, another Th2 cytokine dominantly produced by Th2 cells, also
downregulates FLG expression.75 Furthermore, a recent study has
shown that IL-33, an alarmin that is abundantly stored in kerati-
nocytes, has the potency to downregulate FLG expression as well.76
The original purpose of these immunological modulations against
skin integrity may be to facilitate the desquamation and replace-
ment of damaged corneocytes; however, to achieve this, dysregu-
lation of the skin barrier is essential. A series of these modulations
may cause problems, particularly in AD patients. The exacerbation
loop between congenital barrier deﬁciency and immunogenic
barrier deﬁciency leads to the formation of chronic, persistent skin
inﬂammation in AD.
Barrier dysfunction is leading pathogenesis of skin allergy
It is now evident that epicutaneous antigens are strong sensi-
tizer of allergic disorders. Mouse studies have demonstrated that
food allergy and asthma can be induced via epicutaneous sensiti-
zation and are enhanced under disrupted skin barrier. In human,
sequential acquisition of allergic diseases (atopic march) are
frequently observed in both AD and some genodermatoses, such as
Netherton syndrome (mutation in SPINK5), peeling skin syndrome
1 (Corneodesmosin) and SAM syndrome (Desmoglein1) (Table 1,
bold), which strongly suggests that skin barrier deﬁciency con-
tributes to the development of atopic march. Eosinophilic esoph-
agitis is another chronic immune disorder that is associated with
hypersensitivity to food, and has recently been linked to the mu-
tations in Calpain 14 (CAPN14), a protease speciﬁcally expressed in
the esophagus.77 An in-vitro expriment showed that overactivation
of CAPN14 results in loss of Desmoglein1.78 These studies
demonstrate that barrier deﬁciency in mucosal epithelium also
contribute to the induction of allergic disorders. Recent clinical
trials have shown that epicutaneous antigen exposure induces
Fig. 4. Kallikrein function in the SC. KLKs cleave; 1) corneodesmosomal cadherins and promote desquamation; 2) PAR2 to activation that regulates lipid synthesis and immune
responses; and 3) IL-1 preforms. IL-1 preforms are stored in the cytosol of corneocytes and escape to intercellular space upon cellular damage.
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sensitization while oral antigen consumption induces immune
tolerance.79,80
In the presence of barrier defects in the SC, foreign antigens
readily penetrate into the epidermis and activate innate immune
receptors and pattern recognition receptors. This results in the
production of Th2-promoting cytokines, such as IL-33, IL-25 and
thymic stromal lymphoproteins (TSLP), which are produced by skin
resident cells. Animal studies have demonstrated an essential role
for TSLP in the epicutaneous induction of food allergy with AD-like
skin lesions. Increased TSLP in the epidermis elicits the accumula-
tion of basophils into the skin that promote Th2-cytokine re-
sponses.81 In addition, TSLP signaling on epidermal Langerhans
cells may be important for IgE production during the epicutaneous
sensitization to food allergens.82 The suppressive effect of TSLP on
FLG expressionwas also conﬁrmed by the human skin engrafted on
immunocompromised mice.83
It is noteworthy that cytokine proﬁles in patients with ich-
thyosis vulgaris, who are carrying FLG mutation, have an IL-17-
dominant and low expression level of Th2-related cytokines.84
This immune proﬁle resemble to psoriasis patients, rather than
AD. These ﬁndings suggest that barrier dysfunction alonemight not
induce Th2 immune proﬁles.
Conclusion e therapeutic approach to restore skin barrier
function
Skin barrier deﬁciency and excessive immune responses are two
sides of the same coin in skin allergic diseases, and each is highly
relevant to the other.85 Therefore, therapeutics targeting the skin
barrier function, as well as immunosuppressive drugs, can be
considered important in the effective management of skin allergy.
Recently, two groups investigated whether protecting the skin
barrier with a moisturizer during the neonatal period prevents the
development of AD.86,87 They reported that moisturizer treatment
at an early stage of life resulted in 32e50% less AD prevalence.
These results suggest that to avoid percutaneous sensitization in
the neonatal period by reinforcing the skin barrier function is a
promising strategy to prevent AD.
The potency of FLG replacement therapies has been demon-
strated. This approach includes the application of 1) read-through
drugs, 2) drugs that enhance FLG production, 3) the FLG mono-
mer itself, and 4) FLG metabolites. Read-through drugs are able to
skip the nonsense mutation of the FLG gene, which may be appli-
cable to both heterozygous and homozygous FLGmutation carriers.
Candidate drugs are antimicrobial peptides, such as gentamicin and
PTC124 (Ataluren). These drugs are currently tried in clinical trials
for other genetic diseases.88,89 In contrast, the drugs that enhance
FLG production are only considered applicable to patients with
heterozygous FLG mutations. Candidates include agonists of
peroxisome proliferator-activated receptors (PPARs),90 a serine-
rich diet,91 apigenin,92 JTC801,93 JTE-052,83 and urea.94 All of
these drugs have been demonstrated to induce keratinocyte dif-
ferentiation and increase FLG levels. Further studies are necessary,
however, because their efﬁcacy has only been assessed in vitro or in
animal models.
Intensive research to identify promising candidates to enhance
the skin barrier function is ongoing95 and is expected to lead to
better management of skin allergic diseases, including AD, in the
near future.
Acknowledgement
This study was supported by Grants-in-Aid for Scientiﬁc
Research from the Ministry of Education, Culture, Sports, Science
and Technology of Japan.
Conﬂict of interest
The authors have no conﬂict of interest to declare.
References
1. Brunner PM, Silverberg JI, Guttman-Yassky E, Paller AS, Kabashima K,
Amagai M, et al. Increasing comorbidities suggest that atopic dermatitis is a
systemic disorder. J Invest Dermatol 2017;137:18e25.
2. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin
Immunol 2003;112:S118e27.
3. Egawa G, Kabashima K. Multifactorial skin barrier deﬁciency and atopic
dermatitis: essential topics to prevent the atopic march. J Allergy Clin Immunol
2016;138:350e8. e1.
4. Elias PM, Steinhoff M. “Outside-to-inside” (and now back to “outside”)
pathogenic mechanisms in atopic dermatitis. J Invest Dermatol 2008;128:
1067e70.
5. Otsuka A, Nomura T, Rerknimitr P, Seidel JA, Honda T, Kabashima K. The
interplay between genetic and environmental factors in the pathogenesis of
atopic dermatitis. Immunol Rev 2017;278:246e62.
6. Matsui T, Amagai M. Dissecting the formation, structure and barrier function
of the stratum corneum. Int Immunol 2015;27:269e80.
7. O'Regan GM, Sandilands A, McLean WI, Irvine AD. Filaggrin in atopic
dermatitis. J Allergy Clin Immunol 2009;124:R2e6.
8. Levin J, Friedlander SF, Del Rosso JQ. Atopic dermatitis and the stratum cor-
neum part 1: the role of ﬁlaggrin in the stratum corneum barrier and atopic
skin. J Clin Aesthet Dermatol 2013;6:16e22.
9. Leyvraz C, Charles R-P, Rubera I, Guitard M, Rotman S, Breiden B, et al. The
epidermal barrier function is dependent on the serine protease CAP1/Prss8.
J Cell Biol 2005;170:487e96.
10. Matsui T, Miyamoto K, Kubo A, Kawasaki H, Ebihara T, Hata K, et al. SASPase
regulates stratum corneum hydration through proﬁlaggrin-to-ﬁlaggrin pro-
cessing. EMBO Mol Med 2011;3:320e33.
11. Nachat R, Mechin M-C, Takahara H, Chavanas S, Charveron M, Serre G, et al.
Peptidylarginine deiminase isoforms 1e3 are expressed in the epidermis and
involved in the deimination of K1 and ﬁlaggrin. J Invest Dermatol 2005;124:
384e93.
12. Hoste E, Kemperman P, Devos M, Denecker G, Kezic S, Yau N, et al. Caspase-14
is required for ﬁlaggrin degradation to natural moisturizing factors in the
skin. J Invest Dermatol 2011;131:2233e41.
13. Kamata Y, Taniguchi A, Yamamoto M, Nomura J, Ishihara K, Takahara H, et al.
Neutral cysteine protease bleomycin hydrolase is essential for the breakdown
of deiminated ﬁlaggrin into amino acids. J Biol Chem 2009;284:12829e36.
14. Gibbs NK, Tye J, Norval M. Recent advances in urocanic acid photochemistry,
photobiology and photoimmunology. Photochem Photobiol Sci 2008;7:
655e67.
15. Leitch CS, Natafji E, Yu C, Abdul-Ghaffar S, Madarasingha N, Venables ZC, et al.
Filaggrin-null mutations are associated with increased maturation markers on
Langerhans cells. J Allergy Clin Immunol 2016;138:482e90. e7.
16. Kawasaki H, Nagao K, Kubo A, Hata T, Shimizu A, Mizuno H, et al. Altered
stratum corneum barrier and enhanced percutaneous immune responses in
ﬁlaggrin-null mice. J Allergy Clin Immunol 2012;129:1538e46. e6.
17. Saunders SP, Moran T, Floudas A, Wurlod F, Kaszlikowska A, Salimi M, et al.
Spontaneous atopic dermatitis is mediated by innate immunity, with the
secondary lung inﬂammation of the atopic march requiring adaptive immu-
nity. J Allergy Clin Immunol 2016;137:482e91.
18. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al.
Common loss-of-function variants of the epidermal barrier protein ﬁlaggrin
are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:
441e6.
19. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic
dermatitis. Curr Allergy Asthma Rep 2009;9:265e72.
20. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, et al.
Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol
2009;129:1892e908.
21. Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y,
et al. Loss-of-function mutations in the gene encoding ﬁlaggrin cause ich-
thyosis vulgaris. Nat Genet 2006;38:337e42.
22. Sandilands A, Terron-Kwiatkowski A, Hull PR, O'Regan GM, Clayton TH,
Watson RM, et al. Comprehensive analysis of the gene encoding ﬁlaggrin
uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic
eczema. Nat Genet 2007;39:650e4.
23. Nomura T, Sandilands A, Akiyama M, Liao H, Evans AT, Sakai K, et al. Unique
mutations in the ﬁlaggrin gene in Japanese patients with ichthyosis vulgaris
and atopic dermatitis. J Allergy Clin Immunol 2007;119:434e40.
24. EArly G, Lifecourse EEEC, Australian AGCA, Consortium AAG. Multi-ancestry
genome-wide association study of 21,000 cases and 95,000 controls identiﬁes
new risk loci for atopic dermatitis. Nat Genet 2015;47:1449.
25. Cascella R, Cuzzola VF, Lepre T, Galli E, Moschese V, Chini L, et al. Full
sequencing of the FLG gene in Italian patients with atopic eczema: evidence of
new mutations, but lack of an association. J Invest Dermatol 2011;131:982e4.
26. Winge M, Bilcha K, Lieden A, Shibeshi D, Sandilands A, Wahlgren CF, et al.
Novel ﬁlaggrin mutation but no other loss-of-function variants found in
Ethiopian patients with atopic dermatitis. Br J Dermatol 2011;165:
1074e80.
G. Egawa, K. Kabashima / Allergology International 67 (2018) 3e11 9
27. Thawer-Esmail F, Jakasa I, Todd G, Wen Y, Brown SJ, Kroboth K, et al. South
African amaXhosa patients with atopic dermatitis have decreased levels of
ﬁlaggrin breakdown products but no loss-of-function mutations in ﬁlaggrin.
J Allergy Clin Immunol 2014;133:280e2. e2.
28. Pellerin L, Henry J, Hsu C-Y, Balica S, Jean-Decoster C, Mechin M-C, et al.
Defects of ﬁlaggrin-like proteins in both lesional and nonlesional atopic skin.
J Allergy Clin Immunol 2013;131:1094e102.
29. Margolis DJ, Gupta J, Apter AJ, Ganguly T, Hoffstad O, Papadopoulos M, et al.
Filaggrin-2 variation is associated with more persistent atopic dermatitis in
African American subjects. J Allergy Clin Immunol 2014;133:784e9.
30. Sasaki T, Furusyo N, Shiohama A, Takeuchi S, Nakahara T, Uchi H, et al.
Filaggrin loss-of-function mutations are not a predisposing factor for atopic
dermatitis in an Ishigaki Island under subtropical climate. J Dermatol Sci
2014;76:10e5.
31. Kalinin A, Marekov LN, Steinert PM. Assembly of the epidermal corniﬁed cell
envelope. J Cell Sci 2001;114:3069e70.
32. DiColandrea T, Karashima T, M€a€att€a A, Watt FM. Subcellular distribution of
envoplakin and periplakin insights into their role as precursors of the
epidermal corniﬁed envelope. J Cell Biol 2000;151:573e86.
33. Eckert RL, Sturniolo MT, Broome A-M, Ruse M, Rorke EA. Transglutaminase
function in epidermis. J Invest Dermatol 2005;124:481e92.
34. Candi E, Tarcsa E, Idler WW, Kartasova T, Marekov LN, Steinert PM. Trans-
glutaminase cross-linking properties of the small proline-rich 1 family of
corniﬁed cell envelope proteins integration with loricrin. J Biol Chem
1999;274:7226e37.
35. Nemes Z, Marekov LN, Fesüs L, Steinert PM. A novel function for trans-
glutaminase 1: attachment of long-chain u-hydroxyceramides to involucrin
by ester bond formation. Proc Natl Acad Sci U S A 1999;96:8402e7.
36. Djian P, Easley K, Green H. Targeted ablation of the murine involucrin gene.
J Cell Biol 2000;151:381e8.
37. M€a€att€a A, DiColandrea T, Groot K, Watt FM. Gene targeting of envoplakin, a
cytoskeletal linker protein and precursor of the epidermal corniﬁed envelope.
Mol Cell Biol 2001;21:7047e53.
38. Aho S, Li K, Ryoo Y, McGee C, Ishida-Yamamoto A, Uitto J, et al. Periplakin gene
targeting reveals a constituent of the corniﬁed cell envelope dispensable for
normal mouse development. Mol Cell Biol 2004;24:6410e8.
39. Sevilla LM, Nachat R, Groot KR, Klement JF, Uitto J, Djian P, et al. Mice deﬁcient
in involucrin, envoplakin, and periplakin have a defective epidermal barrier.
J Cell Biol 2007;179:1599e612.
40. Koch PJ, De Viragh PA, Scharer E, Bundman D, Longley MA, Bickenbach J, et al.
Lessons from loricrin-deﬁcient mice compensatory mechanisms maintaining
skin barrier function in the absence of a major corniﬁed envelope protein.
J Cell Biol 2000;151:389e400.
41. Laiho E, Ignatius J, Mikkola H, Yee VC, Teller DC, Niemi K-M, et al. Trans-
glutaminase 1 mutations in autosomal recessive congenital ichthyosis: pri-
vate and recurrent mutations in an isolated population. Am J Hum Genet
1997;61:529e38.
42. Cassidy AJ, van Steensel MA, Steijlen PM, van Geel M, van der Velden J,
Morley SM, et al. A homozygous missense mutation in TGM5 abolishes
epidermal transglutaminase 5 activity and causes acral peeling skin syn-
drome. Am J Hum Genet 2005;77:909e17.
43. Masukawa Y, Narita H, Shimizu E, Kondo N, Sugai Y, Oba T, et al. Character-
ization of overall ceramide species in human stratum corneum. J Lipid Res
2008;49:1466e76.
44. Iwai I, Han H, den Hollander L, Svensson S, €Ofverstedt L-G, Anwar J, et al. The
human skin barrier is organized as stacked bilayers of fully extended
ceramides with cholesterol molecules associated with the ceramide sphingoid
moiety. J Invest Dermatol 2012;132:2215e25.
45. Krieg P, Fürstenberger G. The role of lipoxygenases in epidermis. Biochim
Biophys Acta 2014;1841:390e400.
46. Eckl K-M, de Juanes S, Kurtenbach J, N€atebus M, Lugassy J, Oji V, et al. Mo-
lecular analysis of 250 patients with autosomal recessive congenital ich-
thyosis: evidence for mutation hotspots in ALOXE3 and allelic heterogeneity
in ALOX12B. J Invest Dermatol 2009;129:1421e8.
47. Kelsell PD, Norgett EE, Unsworth H, Teh M-T, Cullup T, Mein CA, et al. Mu-
tations in ABCA12 underlie the severe congenital skin disease harlequin
ichthyosis. Am J Hum Genet 2005;76:794e803.
48. Sasaki T, Shiohama A, Kubo A, Kawasaki H, Ishida-Yamamoto A, Yamada T,
et al. A homozygous nonsense mutation in the gene for Tmem79, a compo-
nent for the lamellar granule secretory system, produces spontaneous eczema
in an experimental model of atopic dermatitis. J Allergy Clin Immunol
2013;132:1111e20. e4.
49. Saunders SP, Goh CS, Brown SJ, Palmer CN, Porter RM, Cole C, et al. Tmem79/
Matt is the matted mouse gene and is a predisposing gene for atopic
dermatitis in human subjects. J Allergy Clin Immunol 2013;132:1121e9.
50. Lundstr€om A, Serre G, Haftek M, Egelrud T. Evidence for a role of corneo-
desmosin, a protein which may serve to modify desmosomes during corni-
ﬁcation, in stratum corneum cell cohesion and desquamation. Arch Dermatol
Res 1994;286:369e75.
51. Samuelov L, Sarig O, Harmon RM, Rapaport D, Ishida-Yamamoto A, Isakov O,
et al. Desmoglein 1 deﬁciency results in severe dermatitis, multiple allergies
and metabolic wasting. Nat Genet 2013;45:1244e8.
52. Oji V, Eckl K-M, Aufenvenne K, N€atebus M, Tarinski T, Ackermann K, et al. Loss
of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy:
unraveling the peeling skin disease. Am J Hum Genet 2010;87:274e81.
53. Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T. A proteolytic
cascade of kallikreins in the stratum corneum. J Invest Dermatol 2005;124:
198e203.
54. Deraison C, Bonnart C, Lopez F, Besson C, Robinson R, Jayakumar A, et al. LEKTI
fragments speciﬁcally inhibit KLK5, KLK7, and KLK14 and control desqua-
mation through a pH-dependent interaction. Mol Biol Cell 2007;18:3607e19.
55. Rippke F, Schreiner V, Doering T, Maibach HI. Stratum corneum pH in atopic
dermatitis. Am J Clin Dermatol 2004;5:217e23.
56. Hachem J-P, Man M-Q, Crumrine D, Uchida Y, Brown BE, Rogiers V, et al.
Sustained serine proteases activity by prolonged increase in pH leads to
degradation of lipid processing enzymes and profound alterations of barrier
function and stratum corneum integrity. J Invest Dermatol 2005;125:
510e20.
57. Kezic S, O'Regan GM, Lutter R, Jakasa I, Koster ES, Saunders S, et al. Filaggrin
loss-of-function mutations are associated with enhanced expression of IL-1
cytokines in the stratum corneum of patients with atopic dermatitis and in
a murine model of ﬁlaggrin deﬁciency. J Allergy Clin Immunol 2012;129:
1031e9. e1.
58. Vasilopoulos Y, Sharaf N, di Giovine F, Simon M, Cork MJ, Duff GW, et al. The
30-UTR AACCins5874 in the stratum corneum chymotryptic enzyme gene
(SCCE/KLK7), associated with atopic dermatitis; causes an increased mRNA
expression without altering its stability. J Dermatol Sci 2011;61:131e3.
59. Hubiche T, Ged C, Benard A, Leaute-Labreze C, McElreavey K, de Verneuil H,
et al. Analysis of SPINK 5, KLK 7 and FLG genotypes in a French atopic
dermatitis cohort. Acta Derm Venereol 2007;87:499e505.
60. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, et al.
Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton
syndrome. Nat Genet 2000;25:141e2.
61. Walley AJ, Chavanas S, Moffatt MF, Esnouf RM, Ubhi B, Lawrence R, et al. Gene
polymorphism in Netherton and common atopic disease. Nat Genet 2001;29:
175e8.
62. Kato A, Fukai K, Oiso N, Hosomi N, Murakami T, Ishii M. Association of SPINK5
gene polymorphisms with atopic dermatitis in the Japanese population. Br J
Dermatol 2003;148:665e9.
63. Zhao L, Di Z, Zhang L, Wang L, Ma L, Lv Y, et al. Association of SPINK5 gene
polymorphisms with atopic dermatitis in Northeast China. J Eur Acad Dermatol
Venereol 2012;26:572e7.
64. Kirschner N, Houdek P, Fromm M, Moll I, Brandner JM. Tight junctions form a
barrier in human epidermis. Eur J Cell Biol 2010;89:839e42.
65. Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, et al. Claudin-
based tight junctions are crucial for the mammalian epidermal barrier a
lesson from claudin-1edeﬁcient mice. J Cell Biol 2002;156:1099e111.
66. Yokouchi M, Kubo A, Kawasaki H, Yoshida K, Ishii K, Furuse M, et al. Epidermal
tight junction barrier function is altered by skin inﬂammation, but not by
ﬁlaggrin-deﬁcient stratum corneum. J Dermatol Sci 2015;77:28e36.
67. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, et al.
Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol
2011;127:773e86. e7.
68. Otberg N, Patzelt A, Rasulev U, Hagemeister T, Linscheid M, Sinkgraven R,
et al. The role of hair follicles in the percutaneous absorption of caffeine. Br J
Clin Pharmacol 2008;65:488e92.
69. Blattner RJ. Molluscum contagiosum: eruptive infection in atopic dermatitis.
J Pediatr 1967;70:997e9.
70. Lynch FW, Evans C, Bolin VS, Steves RJ. Kaposi's varicelliform eruption:
extensive herpes simplex as a complication of eczema. Arch Dermatol
1945;51:129.
71. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A, et al.
Cytokine modulation of atopic dermatitis ﬁlaggrin skin expression. J Allergy
Clin Immunol 2007;120:150e5.
72. Levin J, Fallon Friedlander S, Del Rosso JQ. Atopic dermatitis and the stratum
corneum: part 3: the immune system in atopic dermatitis. J Clin Aesthet
Dermatol 2013;6:37e44.
73. Honda T, Nomura T, Kabashima K. Advances in atopic dermatitis and urticarial
in 2016. J Allergy Clin Immunol 2017;140:369e76.
74. Nomura T, Kabashima K, Miyachi Y. The panoply of abT cells in the skin.
J Dermatol Sci 2014;76:3e9.
75. Cornelissen C, Marquardt Y, Czaja K, Wenzel J, Frank J, Lüscher-Firzlaff J, et al.
IL-31 regulates differentiation and ﬁlaggrin expression in human organotypic
skin models. J Allergy Clin Immunol 2012;129:426e33. e8.
76. Seltmann J, Roesner LM, von Hesler F-W, Wittmann M, Werfel T. IL-33 im-
pacts on the skin barrier by downregulating the expression of ﬁlaggrin.
J Allergy Clin Immunol 2015;135:1659.
77. Kottyan LC, Davis BP, Sherrill JD, Liu K, Rochman M, Kaufman K, et al.
Genome-wide association analysis of eosinophilic esophagitis provides
insight into the tissue speciﬁcity of this allergic disease. Nat Genet 2014;46:
895e900.
78. Davis BP, Stucke EM, Khorki ME, Litosh VA, Rymer JK, Rochman M, et al.
Eosinophilic esophagitiselinked calpain 14 is an IL-13einduced protease that
mediates esophageal epithelial barrier impairment. JCI insight 2016;1.
79. Du Toit G, Sayre PH, Roberts G, Sever ML, Lawson K, Bahnson HT, et al. Effect
of avoidance on peanut allergy after early peanut consumption. N Engl J Med
2016;374:1435e43.
80. Perkin MR, Logan K, Tseng A, Raji B, Ayis S, Peacock J, et al. Randomized trial of
introduction of allergenic foods in breast-fed infants. N Engl J Med 2016;374:
1733e43.
G. Egawa, K. Kabashima / Allergology International 67 (2018) 3e1110
81. Noti M, Kim BS, Siracusa MC, Rak GD, Kubo M, Moghaddam AE, et al. Exposure
to food allergens through inﬂamed skin promotes intestinal food allergy
through the thymic stromal lymphopoietinebasophil axis. J Allergy Clin
Immunol 2014;133:1390e9. e6.
82. Nakajima S, Igyarto BZ, Honda T, Egawa G, Otsuka A, Hara-Chikuma M, et al.
Langerhans cells are critical in epicutaneous sensitization with protein anti-
gen via thymic stromal lymphopoietin receptor signaling. J Allergy Clin
Immunol 2012;129:1048e55. e6.
83. Amano W, Nakajima S, Kunugi H, Numata Y, Kitoh A, Egawa G, et al. The Janus
kinase inhibitor JTE-052 improves skin barrier function through suppressing
signal transducer and activator of transcription 3 signaling. J Allergy Clin
Immunol 2015;136:667e77. e7.
84. Paller AS, Renert-Yuval Y, Suprun M, Esaki H, Oliva M, Huynh TN, et al. An IL-
17edominant immune proﬁle is shared across the major orphan forms of
ichthyosis. J Allergy Clin Immunol 2017;139:152e65.
85. Kabashima K. New concept of the pathogenesis of atopic dermatitis: interplay
among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci 2013;70:
3e11.
86. Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, et al.
Application of moisturizer to neonates prevents development of atopic
dermatitis. J Allergy Clin Immunol 2014;134:824e30. e6.
87. Simpson EL, Chalmers JR, Haniﬁn JM, Thomas KS, Cork MJ, McLean WI, et al.
Emollient enhancement of the skin barrier from birth offers effective atopic
dermatitis prevention. J Allergy Clin Immunol 2014;134:818e23.
88. Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, Al-Dahhak R, et al.
Gentamicin-induced readthrough of stop codons in Duchenne muscular
dystrophy. Ann Neurol 2010;67:771e80.
89. Hoffman EP, Bronson A, Levin AA, Si Takeda, Yokota T, Baudy AR, et al.
Restoring dystrophin expression in duchenne muscular dystrophy muscle:
progress in exon skipping and stop codon read through. Am J Pathol 2011;179:
12e22.
90. Zhang C, Gurevich I, Aneskievich BJ. Organotypic modeling of human kerati-
nocyte response to peroxisome proliferators. Cells Tissues Organs 2012;196:
431e41.
91. Kim H, Lim Y-j, Park J-H, Cho Y. Dietary silk protein, sericin, improves
epidermal hydration with increased levels of ﬁlaggrins and free amino acids
in NC/Nga mice. Br J Nutr 2012;108:1726e35.
92. Hou M, Sun R, Hupe M, Kim PL, Park K, Crumrine D, et al. Topical apigenin
improves epidermal permeability barrier homoeostasis in normal murine skin
by divergent mechanisms. Exp Dermatol 2013;22:210e5.
93. Otsuka A, Doi H, Egawa G, Maekawa A, Fujita T, Nakamizo S, et al. Possible
new therapeutic strategy to regulate atopic dermatitis through upregulating
ﬁlaggrin expression. J Allergy Clin Immunol 2014;133:139e46. e10.
94. Grether-Beck S, Felsner I, Brenden H, Kohne Z, Majora M, Marini A, et al.
Urea uptake enhances barrier function and antimicrobial defense in humans
by regulating epidermal gene expression. J Invest Dermatol 2012;132:
1561e72.
95. Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis:
end of the drought? J Allergy Clin Immunol 2017;140:633e43.
96. Carregaro F, Stefanini ACB, Henrique T, Tajara EH. Study of small proline-rich
proteins (SPRRs) in health and disease: a review of the literature. Arch Der-
matol Res 2013;305:857e66.
97. Matsuki M, Yamashita F, Ishida-Yamamoto A, Yamada K, Kinoshita C,
Fushiki S, et al. Defective stratum corneum and early neonatal death in mice
lacking the gene for transglutaminase 1 (keratinocyte transglutaminase). Proc
Natl Acad Sci U S A 1998;95:1044e9.
98. Bognar P, Nemeth I, Mayer B, Haluszka D, Wikonkal N, Ostorhazi E, et al.
Reduced inﬂammatory threshold indicates skin barrier defect in trans-
glutaminase 3 knockout mice. J Invest Dermatol 2014;134:105e11.
99. de Juanes S, Epp N, Latzko S, Neumann M, Fürstenberger G, Hausser I, et al.
Development of an ichthyosiform phenotype in Alox12b-deﬁcient mouse skin
transplants. J Invest Dermatol 2009;129:1429e36.
100. Krieg P, Rosenberger S, de Juanes S, Latzko S, Hou J, Dick A, et al. Aloxe3
knockout mice reveal a function of epidermal lipoxygenase-3 as hepoxilin
synthase and its pivotal role in barrier formation. J Invest Dermatol 2013;133:
172e80.
101. Yanagi T, Akiyama M, Nishihara H, Ishikawa J, Sakai K, Miyamura Y, et al. Self-
improvement of keratinocyte differentiation defects during skin maturation
in ABCA12-deﬁcient harlequin ichthyosis model mice. Am J Pathol 2010;177:
106e18.
102. Chidgey M, Brakebusch C, Gustafsson E, Cruchley A, Hail C, Kirk S, et al. Mice
lacking desmocollin 1 show epidermal fragility accompanied by barrier de-
fects and abnormal differentiation. Cell Biol 2001;155:821e32.
103. Ruiz P, Birchmeier W. The plakoglobin knock-out mouse: a paradigm for the
molecular analysis of cardiac cell junction formation. Trends Cardiovasc Med
1998;8:97e101.
104. Sklyarova T, Bonne S, D'hooge P, Denecker G, Goossens S, De Rycke R, et al.
Plakophilin-3-deﬁcient mice develop hair coat abnormalities and are prone to
cutaneous inﬂammation. J Invest Dermatol 2008;128:1375e85.
105. Leclerc EA, Huchenq A, Mattiuzzo NR, Metzger D, Chambon P, Ghyselinck NB,
et al. Corneodesmosin gene ablation induces lethal skin-barrier disruption
and hair-follicle degeneration related to desmosome dysfunction. J Cell Sci
2009;122:2699e709.
106. Furio L, de Veer S, Jaillet M, Briot A, Robin A, Deraison C, et al. Transgenic
kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of
Netherton syndrome. J Exp Med 2014;211:499e513.
107. Hansson L, B€ackman A, Ny A, Edlund M, Ekholm E, Hammarstr€om BE, et al.
Epidermal overexpression of stratum corneum chymotryptic enzyme in mice:
a model for chronic itchy dermatitis. J Invest Dermatol 2002;118:444e9.
108. Stefansson K, Brattsand M, Ny A, Glas B, Egelrud T. Kallikrein-related pepti-
dase 14 may be a major contributor to trypsin-like proteolytic activity in
human stratum corneum. Biol Chem 2006;387:761e8.
109. Yang T, Liang D, Koch PJ, Hohl D, Kheradmand F, Overbeek PA. Epidermal
detachment, desmosomal dissociation, and destabilization of corneodesmosin
in Spink5-/-mice. Genes Dev 2004;18:2354e8.
110. Kawagoe J, Takizawa T, Matsumoto J, Tamiya M, Meek SE, Smith AJ, et al.
Effect of protease-activated receptor-2 deﬁciency on allergic dermatitis in the
mouse ear. Jpn J Pharmacol 2002;88:77e84.
G. Egawa, K. Kabashima / Allergology International 67 (2018) 3e11 11
